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ABSTRACT Cardiac calsequestrin (CASQ2) is an intrasarcoplasmic reticulum (SR) low-afﬁnity Ca-binding protein, with
mutations that are associated with catecholamine-induced polymorphic ventricular tachycardia (CPVT). To better understand
how CASQ2 mutants cause CPVT, we expressed two CPVT-linked CASQ2 mutants, a truncated protein (at G11215X,
CASQ2DEL) or CASQ2 containing a point mutation (CASQ2R33Q), in canine ventricular myocytes and assessed their effects on
Ca handling. We also measured CASQ2-CASQ2 variant interactions using ﬂuorescence resonance transfer in a heterologous
expression system, and evaluated CASQ2 interaction with triadin. We found that expression of CASQ2DEL or CASQ2R33Q
altered myocyte Ca signaling through two different mechanisms. Overexpressing CASQ2DEL disrupted the CASQ2 polymer-
ization required for high capacity Ca binding, whereas CASQ2R33Q compromised the ability of CASQ2 to control ryanodine
receptor (RyR2) channel activity. Despite profound differences in SR Ca buffering strengths, local Ca release terminated at the
same free luminal [Ca] in control cells, cells overexpressing wild-type CASQ2 and CASQ2DEL-expressing myocytes, suggesting
that a decline in [Ca]SR is a signal for RyR2 closure. Importantly, disrupting interactions between the RyR2 channel and CASQ2
by expressing CASQ2R33Q markedly lowered the [Ca]SR threshold for Ca release termination. We conclude that CASQ2 in the
SR determines the magnitude and duration of Ca release from each SR terminal by providing both a local source of releasable
Ca and by effects on luminal Ca-dependent RyR2 gating. Furthermore, two CPVT-inducing CASQ2 mutations, which cause
mechanistically different defects in CASQ2 and RyR2 function, lead to increased diastolic SR Ca release events and exhibit a
similar CPVT disease phenotype.
INTRODUCTION
The sarcoplasmic reticulum (SR) is a Ca release and storage
organelle that plays a key role in regulating muscle con-
traction and relaxation. In cardiac muscle, the SR Ca store
provides the majority of Ca required for contractile activation
and it enables the myocardium to relax by resequestering Ca
(1). The release of Ca from the SR, which takes place through
specialized SR Ca release channels (ryanodine receptors,
RyR2), is initiated by a relatively small Ca inﬂux through
sarcolemmal Ca channels during depolarization, a process
known as Ca-induced Ca release (CICR). Ca release to the
cytosol is accompanied by a reciprocal decline in intra-SR
[Ca]; however, only a fraction of the total Ca is normally
released from the SR (2,3) due to RyR2 closure that termi-
nates Ca release (4,5). This RyR2 deactivation is thought to
contribute to subsequent refractoriness of Ca release, which
may limit diastolic SR Ca release and enhance CICR stabil-
ity. It has been suggested that release termination and re-
fractoriness might be caused by a decline in [Ca]SR inhibiting
RyR2 activity (6–9) (i.e., luminal Ca dependent-deactivation
(6)); however, the speciﬁc molecular steps involved in these
processes remain to be deﬁned.
Calsequestrin (CASQ) is a low-afﬁnity, high-capacity Ca
binding protein located within the SR (10,11). CASQ is de-
tected as electron-dense ﬁlamentous matrices localized in the
junctional SR (jSR) and is almost completely absent from the
SR longitudinal network in both skeletal and cardiac muscle
(isoforms CASQ1 and CASQ2, respectively) (12). The ﬁla-
mentous matrices are composed of linear oligomers formed
by CASQ monomers and dimers at Ca concentrations above
1 mM (13–15). The unique distribution and structural orga-
nization of CASQ are believed to be of key physiological
importance although the speciﬁc modes of operation of this
protein only begin to emerge. Due to their proximity to RyRs
the condensed CASQ matrices are thought to provide the
pool of releasable Ca to activate myocyte contraction. In this
regard, condensed CASQ represents the high Ca binding
capacity form of the protein that possesses at least twice the
Ca binding capacity of CASQ monomers in both skeletal and
cardiac muscle (15). CASQ condensation reportedly involves
head-to-tail oligomerization that occurs through front-to-
front and back-to-back dimerization contacts involving
the N- and C-terminal regions of the protein, respectively
(13–15). In addition to serving as a Ca storage site, cardiac
calsequestrin (CASQ2) has been shown to regulate RyR2
activity more directly via protein-protein interactions in-
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volving triadin (TRD) and junctin (Jn) (16). In particular, it
has been proposed that CASQ2 mediates the responsiveness
of the RyR2 channel to luminal Ca by serving as a luminal Ca
sensor (17).
Consistent with a critical role for calsequestrin in main-
taining myocardial function, genetic defects in CASQ2 have
been linked to catecholaminergic polymorphic ventricular
tachycardia (CPVT), a familial form of arrhythmia and sud-
den cardiac death inducible by catecholamine infusion and
exercise (18–20). Seven distinct mutations within the
CASQ2 gene have been linked to CPVT so far (http://
www.fsm.it/cardmoc/) (18–21). Initial characterization of
these mutations has suggested that they act by disrupting
normal SR Ca handling, thereby leading to premature re-
covery of SR Ca release from a luminal Ca-dependent re-
fractory state and causing spontaneous after-Ca transients
and arrhythmogenic delayed after-depolarizations (DADs)
(22,23). However, the speciﬁc details as to how different
mutations, potentially affecting different aspects of CASQ2
function, lead to the same pathophysiological phenotype re-
mains to be determined.
The goal of this study was to investigate the mechanisms
of action of two recently described CPVT-related CASQ2
mutations (referred to here as CASQ2R33Q and CASQ2DEL)
on Ca signaling in cardiac myocytes. CASQ2R33Q is derived
from a CASQ2 allele carrying a missense mutation at nu-
cleotide 99 (G99A), which results in the substitution of a
glutamine for an arginine residue at position 33 (20).
CASQ2DEL is derived from a CASQ2 allele in which nu-
cleotides 339–354 have been deleted (Del.339-354) and re-
sults in a frameshift following the codon for amino acid 112
and introduction of a stop codon after a further ﬁve amino
acids (G11215X) (21). Although expression of both of these
CASQ2 variants led to arrhythmogenic Ca release, the in-
troduction of one variant was associated with a loss of
function, whereas the other with a gain of function effects on
SR Ca release (20,21). To deﬁne the mechanisms of action of
these mutants on Ca signaling we monitored intracellular Ca
cycling in permeabilized myocytes overexpressing wild-type
(WT) or mutant forms of CASQ2 by simultaneously imaging
Ca changes in the cytosolic and SR compartments during
both global (Ca waves) and localized Ca release (Ca sparks).
We also carried out ﬂuorescence resonance transfer (FRET)
measurements and used in vitro afﬁnity binding assays to
assess the effects of the mutations on the ability of CASQ2 to
polymerize and interact with TRD. Our results showed that
expression of CASQ2DEL and CASQ2R33Q altered SR Ca
signaling through two different mechanisms: by disrupting
CASQ2 polymerization required for high capacity Ca bind-
ing and by altering luminal-Ca dependent modulation of the
RyR2 channel by CASQ2. Our studies provided what we
believe is new evidence for the role of Ca in dynamic control
of SR Ca release and showed that CASQ2 plays a dual role as




The coding sequences of the enhanced yellow ﬂuorescent protein (EYFP)
and enhanced cyan ﬂuorescent protein (ECFP) were isolated from the bac-
terial expression vectors pEYFP and pECFP (Clontech) by digestion with
BamHI andNotI. These inserts were ligated into the backbone of the pDsRed-
N1 plasmid (Clontech, Mountain View, CA), from which the DsRed
protein coding region had been removed using the same enzymes. Canine
CASQ2 sequences encoding amino acids 1–343, 1–112, or 1–343 (R33Q)
were ampliﬁed by PCR from pSHUTTLE plasmids carrying either the full
length coding sequence (22) or the sequence containing the R33Q mutation
(20). The PCR primers were designed to introduce a SalI site at the 59 end of
the ampliﬁed sequence and a BamHI site at the 39 end. The sequences of the
three primers are as follows: primer for insertion of SalI site before amino
acid 1: GGCGTCGACGCCATGAAGAGAACACACCTG; insertion of
BamHI site after amino acid 112: GGCGGATCCCCTTCTTCATCAA-
AACC, insertion of BamHI site after amino acid 343: GGCGGATC-
CATCCAGACACTGTCGGC. The PCR products were subcloned and
sequenced to ensure accurate ampliﬁcation. Each insert was subsequently
removed with SalI and BamHI and inserted into the EYFP and ECFP-con-
taining plasmids described above.
Ca imaging
Intracellular Ca imaging was carried out by using an Olympus Fluoview
1000 laser scanning confocal microscope equipped with an Olympus 60X
1.4 N.A. oil objective. Canine ventricular myocytes were enzymatically
isolated as described previously (24), in accordance with the guidelines of the
Ohio State University Institutional Animal Use and Care Committee. Iso-
lated cells were infected with adenoviruses encompassing human WT or
mutant CASQ2s at MOI 100 and kept in culture media for 48 h at 5% CO2/
95% air at 37C as described previously (20–22). Culture media contained:
media 199 M; 5 mM creatine; 5 mM taurine; 25 mM NaHCO3, 5 mM
HEPES, gentamicin 1 mg/ml, penicillin 10 u/ml, and streptomycin 10 mg/ml,
pH 7.3. To simultaneously monitor the intra-SR and cytosolic Ca levels,
myocytes were loaded initially with Fluo-5N AM (10 mM, 4 h, 37C).
Subsequently, myocytes were permeabilized with saponin to remove the
Fluo-5N from the cytoplasm and to introduce Rhod-2 tripotassium salt (30
mM) to the internal solution for cytosolic Ca measurements. The control
intracellular solution contained (mM): 120 potassium aspartate, 20 KCl, 3
MgATP, 10 phosphocreatine, 5 u/ml creatine phosphokinase, 0.2 EGTA and
20 HEPES (pH 7.2). To evoke spontaneous Ca waves EGTA was lowered to
0.05 mM, free [Ca] ;100 nM and free [Mg] ;1 mM. Fluo-5N and Rhod-2
were excited sequentially by 488- and 543-nm laser lines, and ﬂuorescence
was acquired at a rate of 5 ms per line at wavelengths of 500–530 and.560
nm, respectively. For quantitative studies, the temporal dynamics in Fluo-5N
ﬂuorescence was expressed as FSR/FSRmax¼ (F Fcaff)/(Fmax Fcaff), where
F represents ﬂuorescence at time t, Fcaff represents ﬂuorescence level of the
cells after the application of 10 mM of caffeine, and Fmax represents Fluo-5N
ﬂuorescence in the presence of caffeine and 10 mM of [Ca]. [Ca]SR was de-
rived as [Ca]SR ¼ Kd(FSR)/(FSRmax  FSR); where Kd was 400 mM (2). Data
are presented as mean 6 SE. Statistical signiﬁcance was tested with an un-
paired Student’s t-test or one way ANOVA.
FRET experiments
Cultured (DMEM, 37C) 3T3 NIH ﬁbroblasts were lipofected (Polyfect,
Qiagen, Hilden GmbH, Hilden, Germany) with the fusion constructs for
acceptor photobleaching experiments. Fibroblasts were examined 48 h after
transfection using an Olympus Fluoview 1000 spectral laser scanning con-
focal system. Using standard spectroscopic settings, 512 3 512 16-bit XY
images of the cells were taken: CFP and YFP were excited sequentially
frame-by-frame with the 458 and 515 nm lines, respectively, of an argon
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laser. The emitted ﬂuorescence was collected at 475–500 nm for CFP and
530–630 nm for YFP. Repeated scans (10–20 frames) with an unattenuated
515 nm illumination were used to photobleach YFP. CFP ﬂuorescence in-
tensity was measured continuously through the whole experiment and FRET
efﬁciency was estimated using the following equation: (FCFPPostbleach 
FCFPPrebleach)/FCFPPostbleach *100%. Data are reported as mean 6 SE.
Statistical signiﬁcance was tested with an unpaired Student’s t-test.
In vitro binding assay using T7-afﬁnity column
T7-CASQ2 constructs were generated as described previously (21). Re-
combinant CASQ2 proteins were expressed using pET-5a-based plasmids in
BL21 (DE3) Escherichia coli cells (Novagen). Large quantities of T7-
CASQ2 fusion proteins were puriﬁed either by phenyl-Sepharose or T7-tag
afﬁnity column, as described previously (21). SR vesicles (Heavy SR frac-
tion), prepared from rabbit hearts by isopycnic sucrose gradient centrifugation
according to Saito et al. (25), were solubilized for 1 h on ice according to
Zhang et al. (16) and recovered by centrifugation in a Beckman Airfuge at
105,000 3 g for 1 h. Protein concentration was determined according to
Lowry et al. (26). Afﬁnity columns were prepared by immobilizing 30 mg of
T7-CASQ2 fusion proteins on 100 ml of T7-afﬁnity beads for 2 h at 4C.
CHAPS-solubilized SR vesicles were precleared with T7-afﬁnity beads for
2 h at 4C and then incubated with T7-CASQ2 afﬁnity beads for 20 h at 4C.
Bound proteins were eluted by boiling in the SDS sample buffer. SDS-PAGE
was carried outwith 12.5%polyacrylamide gels. Electrophoretic transfer onto
nitrocellulose membrane and Western blot with anti-TRD antibody were
carried out as described (21). Polyclonal antibodies to triadin (Sh33) (27) are a
generousgift fromDr.Kevin P.Campbell (TheUniversity of Iowa, IowaCity,
IA). Statistical signiﬁcance was tested with an unpaired Student’s t-test.
RESULTS
Cytosolic and luminal Ca waves
To gain insights in the mode of operation of CASQ2 in
cardiac myocytes and in the underlying causes of arrhythmia
caused by mutations of these proteins, we have compared the
effects of ectopic expression of two recently described
CPVT-associated CASQ2 variants with either gain or loss of
function effects on SR Ca release, CASQ2R33Q (20) and
CASQ2DEL (21), respectively, in permeabilized canine ven-
tricular myocytes. Myocytes were infected with adenoviruses
carrying the coding region of human CASQ2WT,
CASQ2R33Q (20), or CASQ2DEL proteins (21). Cells infected
with a viral construct containing a short DNA segment served
as controls for viral infection. As we reported previously
(20,21), ectopic expression of WT and R33Qmutant CASQ2
in myocytes resulted in an ;3-fold increase in total CASQ2
with no signiﬁcant changes in native CASQ2 level. Addi-
tionally, expression of CASQ2DEL caused no changes in the
endogenous CASQ2 (Fig. S1 in the Supplementary Material,
Data S1). Permeabilized myocytes allow unrestricted access
to the cytosolic compartments and have been used to study
SR Ca release in different laboratories (6,28). Saponin-per-
meabilized myocytes were kept in an internal solution con-
taining 100 nM free [Ca] (0.05 mM EGTA). Under these
conditions, myocytes generated periodic spontaneous dis-
charges of [Ca]SR, monitored at two optical channels as
waves of cytosolic Ca elevations propagating across the
myocytes and mirrored by reciprocal decreases in [Ca]SR.
Ectopic expression of CASQ2WT or either mutant CASQ2
protein resulted in profound changes in cytosolic and luminal
Ca release signals compared to control (Fig. 1). The fre-
quency of Ca waves was reduced and their cytosolic ampli-
tude was increased in myocytes overexpressing CASQ2WT as
compared to control myocytes (Figs. 1 and 2, A and B). At the
same time, the baseline and maximum depletion (nadir) of
[Ca]SR at the peak of the waves in CASQ2
WT myocytes did
not change although the rate of recovery of the [Ca]SR was
markedly slowed compared to control myocytes (Figs. 1 and 2,
C–E). As we previously shown (29), these effects of over-
expressing WT CASQ2 are attributable to increased Ca buff-
ering and increased amount of releasable Ca in the SR.
Consistent with the arrhythmogenic nature of both CPVT
mutations, the frequency of spontaneous waves was signiﬁ-
cantly higher in myocytes expressing either CASQ2R33Q or
CASQ2DEL compared to control cells (Figs. 1 and 2 A).
However, other characteristics of the waves were affected
differently by the two CASQ2 variants, suggesting different
underlying mechanisms. For example, the amplitude of cyto-
solic Ca waves was signiﬁcantly reduced in CASQ2DEL
myocytes but increased in CASQ2R33Q myocytes with respect
to control (Figs. 1 and 2 B). Additionally, the recovery kinetics
of [Ca]SR were accelerated in CASQ2
DEL -expressing cells but
were slowed in cells expressing CASQ2R33Q or CASQ2WT
(Figs. 1 and 2 E). Furthermore, whereas CASQ2R33Q caused a
signiﬁcant decrease in both baseline and nadir [Ca]SR,
CASQ2DEL had no signiﬁcant effect on these parameters of the
[Ca]SR signal (Fig. 1). Data on Fluo-5N ﬂuorescence and es-
timated [Ca]SR for the four experimental groups are summa-
rized in Fig. 2,C andD, and Table 1. These disparate effects of
the two CPVT mutants might be an indication that the muta-
tions disrupt different aspects of CASQ2 function, speciﬁcally,
its capacity to buffer SR Ca and to modulate RyR2 functional
activity.
Local Ca release and depletion signals
To further investigate the effects of CASQ2 mutants on SR
Ca handling we carried out measurements of elemental Ca
release events, or Ca sparks, along with the associated local
[Ca] depletion signals in the SR (Fig. 3). These signals, also
referred to as ‘‘blinks’’ (3), represent the decline in free [Ca]
at individual jSR elements that are connected to the SR net-
work through diffusion restricting pathways. Overexpression
of CASQWT and CASQ2R33Q increased Ca spark amplitude,
whereas expression of CASQ2DEL decreased Ca spark am-
plitude. The nadir of the local [Ca]SR depletion signal in
CASQ2WT or CASQ2DEL-expressing myocytes were similar
to control (Fig. 3, A,C, andD, and Table 2). At the same time,
the rate of recovery of the local Ca depletion signals was
slowed markedly by CASQ2WT and accelerated by
CASQ2DEL (Fig. 3, A and B). In CASQ2R33Q-expressing
cells the basal and nadir [Ca]SR were lowered as compared to
those in the other three groups (i.e., control, WT and DEL)
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(Fig. 3, A, C, and D, and Table 2) and the rate of [Ca]SR
recovery was slowed similar to CASQ2WT overexpressing
myocytes (Fig. 3, A and B). These results are consistent with
the effects of the CASQ2 variants on SR Ca depletion signals
during ‘‘global’’ Ca waves and present the ﬁrst functional
evidence that CASQ2 resides in jSR cisternae to facilitate and
control Ca release from these subcompartments. As in the
case with the global Ca signals, the reduced Ca spark am-
plitude and accelerated local [Ca]SR recovery in CASQ2
DEL
myocytes is indicative of reduced SR Ca buffering, whereas
the reduced basal and nadir [Ca]SR in CASQ2
R33Q myocytes
is consistent with altered RyR2 function. To further explore
the effects of expressing the two CPVT mutants on SR Ca
buffering, we examined the relationships between the
cytosolic spark amplitude, which is a measure of Ca released,
and the drop of [Ca]SR for individual release events measured
in myocytes from our four experimental groups. The result-
ing plot (Fig. 3 E) shows linear relationships with slopes
roughly proportional to local SR Ca buffering. Both
CASQ2WT and CASQ2R33Q increased buffering whereas
CASQ2DEL decreased it. The ﬁnding that [Ca]SR declined to
the same lowest level suggests that Ca release terminates at a
constant, threshold free luminal [Ca] despite profound dif-
ferences in the amounts of releasable Ca and SR buffer-
ing strengths in the control, CASQ2WT and CASQ2DEL
myocytes. Expression of CASQ2R33Q appears to reduce the
threshold for Ca release termination by affecting RyR2
function. The mechanisms of alterations of SR Ca buffering
and RyR2 function by CASQ2DEL and CASQ2R33Q were
further pursued by studying the effects of these mutant pro-
teins on CASQ2 polymerization and on interaction of
CASQ2 with TRD.
FIGURE 1 Simultaneous measurement of [Ca] changes
during spontaneous Ca waves in the cytosolic and SR
luminal compartments, using the Ca indicators Rhod-2 and
Fluo-5N. Representative images of Ca waves and intra-SR
[Ca] recorded in permeabilized dog ventricular myocytes
overexpressing WT or mutant forms of CASQ2 (48 h after
adenoviral infection). Traces represent time-dependent pro-
ﬁles of cytosolic Rhod-2 and luminal Fluo-5N signals.
Spontaneous Ca waves were induced by lowering [EGTA]
from 200 mM to 50 mM (PCa7) in the internal solution.
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Effects of expression of CPVT-associated
CASQ2 mutants on CASQ2 polymerization
It has been shown by in vitro studies that the polymeric form
of both skeletal and cardiac CASQ possesses higher Ca
binding capacity than monomeric CASQ (15). To test the
hypothesis that ectopic expression of CASQ2DEL reduced SR
Ca binding capacity by impairing polymerization of CASQ2,
we carried out ﬂuorescent label localization and FRET ex-
periments using CASQ2 fusion constructs composed of
either the WT or mutant forms of the protein conjugated with
the ﬂuorescent proteins CFP or YFP expressed in a heterol-
ogous system, 3T3 ﬁbroblasts. These cells have no detectable
FIGURE 2 Characteristics of spontaneous cytosolic and
intra-SR Ca waves. (A–E) Pooled data in control myocytes
and in myocytes overexpressing WT or mutant forms of
CASQ2. Values of spontaneous Ca wave frequency (A);
cytosolic Ca wave amplitude (B); baseline Fluo-5N ﬂuo-
rescence (C); nadir Fluo-5N ﬂuorescence during intra-SR
Ca waves (D); time constant of Fluo-5N ﬂuorescence
recovery after SR Ca waves. (*) Signiﬁcantly different
when compared with control or (y) when compared to cells
overexpressing CASQWT at p, 0.05, one-way ANOVA, n
of waves from 8 to 14, and n of cells from 6 to 10.
TABLE 1 Parameters of global intra-SR Ca depletion signals
FSR FSR/FSRmax [Ca]SR (mM)
Baseline Nadir Baseline Nadir Baseline Nadir
Control 440 6 42 171 6 28 0.72 6 0.07 0.28 6 0.02 1.04 6 0.11 0.16 6 0.02
WT 364 6 54 138 6 16 0.66 6 0.09 0.25 6 0.01 0.78 6 0.15 0.13 6 0.01
DEL 416 6 20 162 6 12 0.69 6 0.03 0.27 6 0.01 0.88 6 0.07 0.15 6 0.01
R33Q 224 6 28*y 104 6 16*y 0.43 6 0.05*y 0.19 6 0.02*y 0.30 6 0.08*y 0.09 6 0.01*y
Global intra-SR Fluo-5N signals and estimated [Ca]SR in permeabilized myocytes infected with control adenovirus and adenoviral constructs encoding
WT CASQ2, DEL, and R33Q CASQ2mutants. FSR¼ F FCAFF; FSRmax¼ Fmax FCAFF; and [Ca]SR¼ Kd(FSR)/(FSRmax FSR), whereKd was 400 mM (2).
*Signiﬁcantly different if compared with control or yif compared with WT, p , 0.05, one-way ANOVA, n of waves from 14 to 18, n of cells from 6 to 10.
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levels of endogenous CASQ2 that would interfere with our
FRET measurements by binding to the fusion constructs. We
coexpressed WT CASQ2 conjugated with CFP (CASQ2WT-
CFP) with the YFP-tagged CASQ2 variants CASQ2WT-YFP,
CASQ2DEL-YFP, or CASQ2R33Q-YFP. In the FRET exper-
iments, CFP (illuminated at 458 nm) served as a donor and
YFP served as acceptor and FRET efﬁciency was measured
as a relative increase of CFP ﬂuorescence at 475–500 nm
after photobleaching YFP with unattenuated 515 nm laser.
Representative images of 3T3 ﬁbroblasts cotransfected with
CASQ2WT-CFP and CASQ2WT-YFP, CASQ2DEL-YFP, or
CASQ2R33Q-YFP before and after acceptor photobleaching
are shown in Fig. 4. Both CFP and YFP-tagged WT CASQ2
showed a characteristic distribution limited to well-deﬁned
puncta in the cells. Such punctate distribution of CASQ1 has
been described previously and attributed to CASQ1 mono-
mers aggregating into clusters of supramolecular complexes
within the ER or SR in myotubes (14). Consistent with this
FIGURE 3 Simultaneous measurement of
[Ca] changes during spontaneous Ca sparks in
the cytosolic and SR luminal compartments
with the Ca indicators Rhod-2 and Fluo-5N.
(A) Representative images of Ca sparks (upper
panel) and local intra-SR [Ca] depletion signals
(‘‘blinks’’) recorded simultaneously with Rhod-2
and Fluo-5N, respectively, in permeabilized
canine ventricular myocytes overexpressing
WT or mutant forms of CASQ2 (48 h after
adenoviral infection). Traces at the bottom rep-
resent time-dependent proﬁles of Rhod-2 and
Fluo-5N signals; (B) Pooled data for the time
constant of recovery of intra-SR Ca depletion
signals in control myocytes and in myocytes
expressing WT or mutant forms of CASQ2; (C)
Pooled data for the nadir of intra SR local [Ca]
depletion signals in the same groups of cells as
in (B). *Signiﬁcantly different when compared
with myocytes infected with control virus or (y)
when compared with myocytes overexpressing
CASQWT at p , 0.05, one-way ANOVA, n of
blinks from 13 to 16, n of cells from 8 to 13. (D)
Histogram presentation of the data for the nadir
of intra SR [Ca] depletion signals. (E) Relation-
ships between cytosolic Ca spark amplitude and
the amplitude of the corresponding [Ca]SR de-
pletion signal (FBasal  FNadir) for individual
pairs of events measured in control cells and in
cells expressing the DEL, WT, and R33Q
CASQ2 variants, respectively. The data are ﬁt
by a linear regression (solid lines) with slopes of
6.8, 2.6, 12.1, and 13.4 for Control and the
DEL, WT, and R33Q CASQ2 variants, respec-
tively.
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view coexpressed CASQ2WT-CFP and CASQ2WT-YFP
produced a highly efﬁcient FRET manifest by increased
brightness of CFP ﬂuorescence after acceptor photodestruction.
CASQ2 polymerization is thought to be dependent on [Ca]
such that polymerization is promoted at elevated [Ca]
whereas monomers predominate at lower [Ca]. Therefore we
investigated the effects of loading and depleting the ER Ca
stores on both distribution of CASQ2 and FRET between
CFP and YFP tagged CASQ2 monomers. As illustrated by
Fig. 5 A depletion of the ER stores by application of 1 mM
ionomycin in the presence of 5 mM EGTA resulted in a
marked decrease in FRET efﬁciency. The Ca concentration
dependence of FRET, obtained by using several different Ca
concentrations in the incubation medium, was characterized
by a sigmoidal function with EC50 ; 500 mM and cooper-
ativity of 1 (Fig. 5 C). The Ca-dependence of FRET is in
agreement with in vitro and in situ estimates of Ca binding to
CASQ (10,30) (EC50 ; 500 mM).
FIGURE 4 Acceptor photobleaching experiments in ﬁ-
broblasts coexpressing CASQ2 WT-CFP fusion protein
with WT or mutant forms of CASQ2 fused with YFP.
Representative confocal images of CFP and YFP ﬂuores-
cence acquired from ﬁbroblasts cotransfected with
CASQ2WT-CFP and CASQ2WT-YFP (A), CASQR33Q-
YFP (B), or CASQ2DEL-YFP (C) fusion constructs before
and after photodestruction of YFP. (D) Cells expressing the
CASQ2WT-CFP/CASQ2WT-YFP FRET pair together with
the adenovirally delivered CASQ2DEL mutant. All mea-
surements were carried out 36–48 h after transfection of
cells with fusion constructs and infection with the adeno-
viral constructs.
TABLE 2 Parameters of local intra-SR Ca depletion signals
FSR FSR/FSRmax [Ca]SR (mM)
Baseline Nadir Baseline Nadir Baseline Nadir
Control 370 6 15 256 6 8 0.74 6 0.03 0.51 6 0.01 1.12 6 0.13 0.42 6 0.01
WT 376 6 47 270 6 38 0.75 6 0.09 0.54 6 0.08 1.22 6 0.25 0.48 6 0.09
DEL 401 6 19 287 6 14 0.73 6 0.03 0.52 6 0.03 1.08 6 0.16 0.45 6 0.05
R33Q 202 6 20*y 128 6 12*y 0.47 6 0.05*y 0.31 6 0.03*y 0.37 6 0.12*y 0.18 6 0.03*y
Local intra-SR Fluo-5N signals and estimated [Ca]SR in permeabilized myocytes infected with control adenovirus and adenoviral constructs encoding
WT CASQ2, DEL, and R33Q CASQ2 mutants. FSR¼ F FCAFF; FSRmax¼ Fmax FCAFF; and [Ca]SR¼ Kd(FSR)/(FSRmax FSR), where Kd was 400 mM (2).
*Signiﬁcantly different if compared with control or yif compared with WT, p , 0.05, one-way ANOVA, n of blinks from 13 to 16, n of cells from 8 to 13.
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It has been suggested that cyclical changes in CASQ2
polymerization may occur in cardiac myocytes on a beat to
beat basis (15). We directly examined this possibility by
assessing the rate of depolymerization of WT CASQ2 on
lowering [Ca] using FRET measurements. Maximum FRET
was obtained by exposing ionomycin-treated cells to 10 mM
Ca; then Ca was removed (0 Ca) and FRET efﬁciency values
determined at different time points (Fig. 5 D). As indexed by
the time course of FRET decrease, CASQ2 depolymerization
occurred with a time constant of;18.1 min (Fig. 5D), which
is too slow on the timescale of the cardiac cycle. Similar
results were obtained when instead of using ionomycin, the
ER stores of saponin-permeabilized cells were rapidly de-
pleted by application of the IP3 receptor agonist adenophostin
(10 mM) and the SERCA pump inhibitor thapsigargin (10
mM) (not shown). Collectively, these results with expression
of CASQ2WT indicate that CASQ2 aggregates in cells and
this process is Ca-dependent but apparently too slow to occur
on the timescale of the cardiac cycle.
Cellular distribution and polymerization of
CASQ2DEL and CASQ2R33Q
The results obtained with coexpression of the CASQ2WT and
CASQ2DEL constructs were markedly different from those
obtained in cells expressing CASQ2WT alone. Instead of the
well-deﬁned punctate labeling pattern observed in
CASQ2WT-expressing cells, cells coexpressing CASQ2WT
and CASQ2DEL exhibited a much less deﬁned and
more diffuse labeling pattern (Fig. 4). A similar diffuse pat-
tern was apparent for both CASQ2WT and CASQ2DEL (as
shown by CFP and YFP ﬂuorescence) and has been described
previously for CASQ1 mutants that lacked the ability to
polymerize (14). Our results suggest that CASQ2DEL is not
only unable to self-polymerize but also acts in a dominant
negative manner to disrupt the ability of CASQ2WT to form
multimolecular complexes. Consistent with these changes in
ﬂuorescence labeling, cells coexpressing CASQ2WT and
CASQ2DEL did not exhibit a signiﬁcant FRET signal irre-
spective of Ca presence. Moreover, adenovirus-mediated
expression of CASQ2DEL reduced energy transfer between
CASQ2WT-CFP and CASQ2WT-YFP and altered the
CASQ2WT distribution pattern in ﬁbroblasts (Figs. 4 and
5 B). The dispersive effect of the DEL mutant on distribution
of WT CASQ2 was further conﬁrmed in immunocyto-
chemistry experiments with expression of untagged WT and
DEL CASQ2 proteins (Fig. 2S, Data S1).
In contrast to the effects of CASQ2DEL, ectopic expression
of CASQ2R33Q exerted no discernible impact on CASQ2
distribution (Fig. 4). The ability to generate FRET and its Ca
dependence was also generally preserved (Fig. 5 A). In fact
the Ca dependency of FRET between CASQ2WT and
CASQ2R33Q exhibited a substantial leftward shift (EC50 ¼
51 mM, Fig. 5 C). Taken together our results suggest that
the reduced Ca buffering capacity of myocytes express-
ing CASQ2DEL can be ascribed to disruption of CASQ2
polymerization required for high capacity Ca binding. These
FIGURE 5 Polymerization of WT and mutant CASQ2s
in living cells. (A) Pooled data for FRET efﬁciency in 3T3
ﬁbroblasts coexpressing WT and mutant CASQ2 at 0 [Ca]
(5 mM EGTA in the solution), or in the presence of 10 mM
[Ca] (n from 18 to 28). Cells were exposed to 1 mM of
ionomycin. (B) Pooled data for FRET efﬁciency in cells
expressing WT CASQ2 CFP/YFP infected with adenoviral
Ad-CASQ2WT or Ad-CASQ2DEL constructs at 10 mM [Ca]
(n ¼ 14 and 15 respectively). (C) Pooled data for efﬁciency
of FRET between CASQ2WT-CFP and CASQ2WT-YFP or
CASQ2R33Q-YFP at different Ca concentrations. Data
points (n from 18 to 24) were ﬁtted using logistic functions
with EC50 values 509 and 51 mmol/L for FRET to
CASQ2WT and CASQ2R33Q, respectively. (D) Time-de-
pendent changes in FRET efﬁciency after application of 10
mM [Ca] (solid triangles) or 0 [Ca] (5 mM EGTA, open
circles) to ﬁbroblasts in the presence of 1 mM ionomycin.
Data presented as mean 6 SE; n from 14 to 23. Data for 0
[Ca] were ﬁtted with a singe exponential function with time
constant of 18.1 min.
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results also indicate that in contrast to CASQ2DEL, ectopic
expression of CASQ2R33Q has minimal impact on CASQ2
polymerization, consistent with the view that this mutation
affects SRCa release by altering the activity of theRyR2channel
rather than by compromising CASQ2 Ca binding activity.
Interaction of CASQ2DEL and CASQ2R33Q
with triadin
It has been shown previously that CASQ2 modulates RyR2
function through interaction with TRD (17). To test the
possibility that the CASQ2 mutations under study altered the
ability of CASQ2 to interact with TRD, we carried out in
vitro binding measurements using afﬁnity chromatography
(Fig. 6). In agreement with previous reports (16), TRD in-
teracted with WT CASQ2 in a Ca-dependent manner, i.e., the
binding was stronger at 0 [Ca] (1 mM EGTA) than at 1 mM
[Ca] (Fig. 6, B and C). Although the mean values for
CASQ2R33Q binding to TRD showed a tendency to be lower
as compared to those for CASQ2WT in both the presence and
absence of CaCl2 these changes where not statistically sig-
niﬁcant (Fig. 6 C). CASQ2DEL exhibited no detectable
binding to TRD in the presence (Fig. 6 B) and absence of
Ca (data not shown). Because this mutant lacks the entire
C-terminal region, these results are consistent with the pos-
sibility that the TRD binding domain of CASQ2 resides in its
C-terminal region as suggested for the skeletal isoform of the
protein (31). These results also suggest that the effects of
expression of CASQ2DEL on myocyte Ca handling do not
involve direct actions of the protein on the RyR2 channel
complex. On the other hand, because the R33Qmutant is able
to bind TRD, ectopic expression of this mutant may alter Ca
handling by displacing endogenous CASQ2 from the RyR2
channel complex.
DISCUSSION
In this study, we compared the effects of expression of two
recently identiﬁed CASQ2 variants DEL and R33Q associ-
ated with CPVT (20,21), on local SR Ca signaling in cardiac
myocytes. Ectopic expression of these CASQ2 variants al-
tered myocyte Ca signaling through two different mecha-
nisms: by disrupting CASQ2 polymerization required for
high capacity Ca binding and by impairing the ability of
CASQ2 to modulate RyR2 function. Our results showed that
CASQ2 polymerization is a critical factor in determining the
buffering function of CASQ2 and provided what we believe
is new evidence for the role of luminal Ca and CASQ2 in
termination of SR Ca release. These ﬁndings are summarized
in Fig. 7.
CASQ2 as a local Ca buffer
Classical EM studies showed that skeletal and cardiac CASQ
forms an electron-dense matrix in the lumen of the junctional
SR, in the proximity of RyRs (12). However, the functional
signiﬁcance of this unique organization has not been clearly
established. Our simultaneous measurements of focal extra-
and intra-SR Ca signals (i.e., Ca sparks and ‘‘blinks’’) in
myocytes expressing the WT and mutant CASQ2 have pro-
vided functional evidence for the ability of CASQ2 to buffer
Ca locally, i.e., within individual junctional SR cisternae,
FIGURE 6 In vitro binding of TRD with either WT or mutant forms of
T7-tagged CASQ2. Puriﬁed CASQ2 afﬁnity beads were incubated with
CHAPS-solubilized cardiac heavy SR vesicles (100 mg) in the presence of
1 mMCaCl2 (A, B). After washing several times, bound proteins were eluted
by SDS-sample buffer, subjected to SDS-PAGE and partly stained with
Coomassie blue (A, shaded arrowheads point to CASQ2) and partly
transferred to a nitrocellulose sheet and immunostained with anti-TRD
antibodies (B, TRD c and TRD indicate glycosylated and unglycosilated
forms of TRD, respectively). Lane 1, CASQ2WT afﬁnity beads; lane 2,
CASQ2R33Q afﬁnity beads; lane 3, CASQ2DEL afﬁnity beads; and lane 4,
blank, afﬁnity beads without any sample. Molecular mass standards are
indicated by arrowheads on the right-hand side. (C) Summary of densito-
metric data obtained for CASQ2WT and CASQ2R33Q in the presence of
either 1 mM CaCl2 (n ¼ 5) or 1 mM EGTA (n ¼ 4).
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conﬁrming the idea that CASQ2 serves to concentrate Ca at
the sites of SR Ca release to facilitate Ca signaling by RyR2s.
In particular, our data showed that overexpression of WT
CASQ2 increased both the amount of Ca released during a Ca
spark and the time required for reﬁlling of an individual jSR
store after local Ca release indicative of enhanced Ca buff-
ering within this structure (Fig. 3). At the same time, dis-
rupting CASQ2 polymerization by expressing CASQ2DEL
resulted in reduced local Ca release and accelerated recovery
of [Ca]SR, consistent with reduced Ca buffering inside the
jSR. Thus, polymerized CASQ2 within the jSR enables in-
dividual jSR cisternae to operate as functionally independent
Ca storage and release sites with their own reserve of re-
leasable Ca. Because the amount of CASQ2 sequestered near
the RyR2s is critical in determining the ‘‘quanta’’ of Ca re-
leased during elementary Ca release events, CASQ2 should
be viewed as part of the Ca release unit along with the RyR2
clusters it is functionally and structurally associated with.
Cyclical changes in CASQ2 polymerization have been
proposed to occur in cardiac myocytes and regulate the level
of free intra-SR Ca on a beat-to-beat basis (15). This attrac-
tive hypothesis is based on in vitro effects of Ca as well as
those of pH and potassium ions on CASQ2 structural tran-
sitions. However, our direct measurements of the time course
of CASQ2 polymer disassembly using FRET indicated that
this process is too slow (minutes rather than seconds) to occur
on the timescale of the cardiac cycle (Fig. 5 D).
Role of luminal Ca and CASQ2 in termination of
local SR Ca release
In addition to shedding new light on the role of CASQ2 as a
local Ca buffer, our studies also yielded what we believe is
new evidence for the role of CASQ2 and luminal Ca in dy-
namic modulation of SR Ca release. We found that regardless
of the amount of total Ca present in the SR, both global and
local Ca release terminated always at a certain threshold free
luminal [Ca]. For example, the local free [Ca]SR depletion sig-
nals during sparks fell to the same lowest value in myocytes
expressing CASQ2WT or CASQ2DEL (Fig. 3). This occurred
despite the fact that the amount of SR Ca buffering and total Ca
released were increased by overexpression of CASQWT but
reduced by overexpression of CASQ2DEL. Importantly, we
were able to alter the [Ca]SR threshold for Ca release termina-
tion by disrupting interactions of CASQ2 with the RyR2
complex. This was achieved by expressing CASQ2R33Q with a
‘‘gain in function’’ effects on Ca spark frequency (20), which
not only reduced the basal [Ca]SR (due to increased SRCa leak)
but also lowered the nadir of Ca depletion signals during both
global and local Ca release with respect to the other experi-
mental groups (Figs. 1, 2 D, and 3, A, C, and D, and Tables
1 and 2). These ﬁndings provide strong support for the hy-
pothesis that changes in luminal Ca serve an important role in
Ca release termination and that CASQ2 is involved in medi-
ating the effects of luminal Ca on the RyR2 channel (17).
Modes of action of DEL and R33Q on SR
Ca release
In accord with our previous studies (21), ectopic expression
of CASQ2DEL in cardiac myocytes resulted in a marked de-
crease in the amplitude of spontaneous Ca transients and Ca
sparks, thus showing a pronounced dominant negative effect
of the mutant on the functional size of the Ca stores. In
principle, such a dominant negative effect could be attribut-
able to either impairment of CASQ2 polymerization required
for high capacity Ca binding and/or to disrupted interaction
of CASQ2 with the RyR2 channel complex, leading to leaky
FIGURE 7 Disruption of Ca storing and reg-
ulatory functions of CASQ2 by the CPVT
CASQ2 mutants DEL and R33Q. CASQ2 is
present in the junctional SR in two forms (left-
hand scheme): polymeric CASQ2 with high Ca
binding capacity serves as a Ca storage site and
controls [Ca]SR in the vicinity of RyR2; mono-
meric CASQ2 regulates RyR2 activity in a
[Ca]SR-dependent manner (through binding to
TRD). Ca release by RyR2s results in partial
depletion of [Ca]SR and the release is terminated
at a certain threshold [Ca]SR ([Ca]SRT). After
their deactivation, RyR2s stay refractory until
the jSR is reﬁlled with Ca, a process that is
inﬂuenced by CASQ2 Ca buffering capacity.
Expression of CASQ2DEL disrupts CASQ2 po-
lymerization and reduces SR Ca buffering with-
out altering interactions of WT CASQ2 with the
RyR2 complex (middle). This results in accelerated recovery of [Ca]SR and hence shortened restitution from luminal-Ca dependent deactivation that follows SR
Ca release. Expression of CASQ2R33Q displaces WT CASQ2 from the RyR2 complex without interfering with polymerization and Ca buffering (right). This
impairs the ability of CASQ2 to act as a luminal Ca sensor, i.e., inhibit RyR2 activity at low luminal Ca, resulting in lowered [Ca]SRT and shortened Ca
signaling refractoriness. Thus, both CPVTmutant proteins act by disrupting normal control of RyR2 by CASQ2 and luminal Ca required for efﬁcient turning of
Ca release during the diastolic phase.
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RyR2s and depleted SR Ca stores. Based on several key
pieces of experimental evidence we propose that CASQ2DEL
acted through the former rather than through the latter
mechanism. Speciﬁcally, although expression of CASQ2DEL
reduced the intra-SR Ca buffering (as evidenced by accel-
erated recovery kinetics of [Ca]SR after SR Ca release) the
steady-state free [Ca]SR was not altered (Figs. 1 and 2, C and
E, and Table 1). Because the steady-state [Ca]SR is deter-
mined by the balance between SR Ca uptake and leak the fact
that this parameter was not affected in our experiments
strongly suggests that CASQ2DEL does not alter the func-
tional activity of RyR2s. In accord with this conclusion, our
in vitro binding experiments detected no physical interac-
tions between CASQ2DEL and TRD, the putative mediator of
CASQ2’s inﬂuence on the RyR2 channel (Fig. 6). At the
same time, our ﬂuorescent tag localization, immunocyto-
chemistry, and FRET experiments showed that the mutant
protein not only lacked the capacity of CASQ2 to self-po-
lymerize but disrupted the ability of CASQ2WT to form su-
pramolecular complexes in a homologous expression system
(Figs. 4 and 5, A and B, and Fig. S2, Data S1). Because po-
lymerized CASQ2 represents the high Ca binding capacity
form of the protein (15) disruption of polymerization could
account for the dominant negative effects of CASQ2DEL on
SR Ca storing capacity (Fig. 7, middle). Thus collectively,
these ﬁndings suggest that expression of CASQ2DEL alters
myocytes Ca handling by disrupting CASQ2 polymerization.
In comparison, expression of CASQ2R33Q increased the
SR Ca leak and led to a reduction in free steady-state [Ca]SR,
without affecting SR Ca binding capacity, as evidenced by
the lack of an effect on recovery kinetics of [Ca]SR after SR
Ca release (Figs. 1 and 2, C and E, and Table 1) or intra-SR
Ca buffering slope (Fig. 3 E). Additionally, based on the
results of ﬂuorescent labeled protein localization and FRET
experiments, this mutant did not affect the ability of CASQ2
to polymerize (Figs. 4 and 5 A). CASQ2R33Q also retained an
ability to bind to TRD albeit less strongly than its WT
counterpart (Fig. 6). Interestingly, despite its ability to
physically associate with TRD, CASQ2R33Q lacks the efﬁ-
ciency of CASQ2WT to inhibit RyR2 function in lipid bila-
yers (20). Thus, the gain-of-function effects of this mutant on
SR Ca release in CASQ2R33Q-expressing myocytes could be
ascribed to the mutant displacing endogenous CASQ2 with
an inhibitory action from the RyR2 complex (Fig. 7, right).
Relevance to CPVT
Based on our present as well as previous studies in myocytes
we can distinguish two principal mechanisms as to how
CASQ2mutations lead to arrhythmogenic disturbances in Ca
transients and electrical activity. Both mechanisms act by
disrupting the normal control of RyR2s by luminal Ca and
CASQ2 required for efﬁcient turning off Ca release during
the diastolic phase (Fig. 7, left). Shortened and reduced Ca
signaling refractoriness results in spontaneous Ca release and
arrhythmogenic DADs, as shown previously in myocytes
expressing CPVT CASQ2 mutants, including R33Q and
DEL (20,21). In case of mutations that reduce CASQ2
abundance and/or Ca binding activity (DEL), shortened re-
fractoriness is caused by premature recovery of [Ca]SR in the
vicinity of RyR2s (Fig. 7, middle). With mutations that dis-
rupt CASQ2 interaction with RyR2 (via TRD, e.g., R33Q
(20) and D307H (32)), the same effect is attributable to im-
paired ability of CASQ2 to act as a luminal Ca sensor i.e.,
inhibit RyR2 at low [Ca]SR (Fig. 7, right). SERCA activity is
also an important factor in determining the rate of reﬁlling of
the SR and hence the duration of luminal Ca dependent re-
fractoriness (8), and stimulation of SERCA (via PLB) is
likely to explain the dependence of arrhythmia on adrenergic
stimulation.
In animal models of CPVT or clinical settings when only
the mutant form of the protein is present (i.e., homozygous
carries), the two mechanisms affecting either the buffering or
modulatory function of CASQ2 are likely to act in parallel to
induce the CPVT phenotype. For example, a complete lack of
CASQ2 would be expected to both alter intra-SR Ca buff-
ering and directly affect RyR2 gating. Additionally, com-
pensatory changes, including SR volume expansion (33) and
upregulation of the SR Ca binding protein calreticulin (34)
are also likely to inﬂuence manifestations of CPVT under
chronic settings. Such compensatory changes along with
differences in mutant protein expression levels (34) under
conditions of chronic versus acute settings are likely to ac-
count for the fact that CPVT is observed only in homozygous
carriers despite the dominant negative effects of the mutants
in our experiments. Finally, it is to be noted that although our
results provide insights into molecular and subcellular basis
of CPVT, it remains to be deﬁned how abnormalities in Ca
homeostasis and DADs in a single myocardial cell cause an
arrhythmia in the whole heart. Recently, evidence for an
important role of myocardial conduction system, namely
Purkinje cells, in arrhythmogenesis in CPVT has been pre-
sented (35).
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